Abstract:The mitochondrial DNA (mtDNA) 12S rRNA is a hot spot for mutations associated with both aminoglycoside-induced and nonsyndromic hearing loss. Of those, the homoplasmic A1555G and C1494T mutations at a highly conserved decoding region of the 12S rRNA have been associated with hearing loss. These two mutations account for a significant number of cases of aminoglycoside ototoxicity. The A1555G or C1494T mutation is expected to form novel 1494C-G1555 or 1494U-A1555 base-pair at the highly conserved A-site of 12S rRNA. These transitions make the secondary structure of this RNA more closely resemble the corresponding region of bacterial 16S rRNA. Thus, the new U-A or G-C pair in 12S rRNA created by the C1494T or A1555G transition facilitates the binding of aminoglycosides, thereby accounting for the fact that the exposure to aminoglycosides can induce or worsen hearing loss in individuals carrying these mutations. Biochemical characterization demonstrated an impairment of mitochondrial protein synthesis and subsequent defects in respiration in cells carrying the C1494T or A1555G mutation. Furthermore, the growth defect and impairment of mitochondrial translation in DMEM medium in the presence of high concentration of paromomycin or neomycin were observed in cell lines carrying the A1555G or C1494T mutation as compared to the average rate in control cell lines. These observations provide the direct genetic and biochemical evidence that the A1555G or C1494T mutation is a pathogenic mtDNA mutation associated with aminoglycoside-induced and nonsyndromic hearing loss. Therefore, these data provide valuable information and technology to predict: (1) which individuals are at risk for ototoxicity, (2) to improve the safety of aminoglycoside antibiotic therapy; and (3) eventually to decrease the incidence of deafness.

Aminoglycoside Ototoxicity: Prevention in Sight?

Finding Ways to Solve or Prevent Aminoglycoside-Induced Ototoxicity?

A Biochemical Basis for the Inherited Susceptibility to Aminoglycoside Ototoxicity

Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic.

Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity

Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides

Mitochondrial DNA Mutations Associated with Aminoglycoside Ototoxicity

Prevalence of Mitochondrial 12s Rrna Mutation Associated with Aminoglycoside Ototoxicity

Interaction of Aminoglycosides with Human Mitochondrial 12S Rrna Carrying the Deafness-Associated Mutation

Damaging Effects of Aminoglycoside Antibiotics on Cochlear Spiral Ganglion Neurons

Mechanisms and otoprotective strategies of programmed cell death on aminoglycoside-induced ototoxicity

The design and screening of drugs to prevent acquired sensorineural hearing loss

Genetic Factors in Aminoglycoside Toxicity

Research Advances in Prevention &cure of Ototoxicity Caused by Aminoglycoside Antibiotics Using Traditional Chinese Medicines

Role of Neurotrophins and Lectins in Prevention of Ototoxicity

[Ototoxic mechanism of aminoglycoside antibiotics--role of glutaminergic NMDA receptors]

Protection of Hair Cells from Ototoxic Drug-Induced Hearing Loss.

Functional and morphological analysis of different aminoglycoside treatment regimens inducing hearing loss in mice

Anti-inflammatory Therapy Protects Spiral Ganglion Neurons After Aminoglycoside Antibiotic-Induced Hair Cell Loss

Galangin prevents aminoglycoside-induced ototoxicity by decreasing mitochondrial production of reactive oxygen species in mouse cochlear cultures

Protection for medication-induced hearing loss: the state of the science